drugset / Trial / NCT07468526
An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria
Phase 3
Not yet recruiting
1019 enrolled
Menzies School of Health Research
Aga Khan University · collabArba Minch University · collabCurtin University · collabJimma University · collabPapua New Guinea Institute of Medical Research · collabPathWest Laboratory Medicine WA · collabUniversitas Sumatera Utara · collabUniversity of Melbourne · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Current treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in Papua New Guinea (PNG) suggests a shortened treatment of 3 days is safe and effective. Our multicentre trial will assess the safety and efficacy of an ultra-short primaquine course. This trial is expected to directly influence global treatment policies.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2027-12-01
- Completion
- 2028-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Primaquine | Small molecule | 1 mg/kg | — |